One concrete shift for TG Therapeutics this year was the push to simplify and broaden BRIUMVI use, from single 600 mg Day 1 infusions in relapsing multiple sclerosis to new trials in conditions like myasthenia gravis and treatment-resistant schizophrenia. Investors who held TG Therapeutics from the start of the year are up 98.4%, including dividends. If you were deciding on 1 January, what needed to be true about that lone franchise and margin path to make such a decision feel sensible?
TG Therapeutics is not the only name tied to this theme. Zero in on 36 healthcare AI stocks and compare how each one is priced.
The Two Stories TG Therapeutics Investors Were Really Buying
The shares cost US$29.81 at the start of the period, and anyone looking at TG Therapeutics had to decide which story felt more realistic.
On the optimistic side, the bull Narrative pointed to a Fair Value of US$40.5 as the price implied if assumptions played out. This was built on BRIUMVI driving long term revenue growth and profit margin expansion, supported by a lean cost base and broader access.
The bear Narrative argued for a Fair Value of US$11, anchored in the risk that reliance on BRIUMVI, pricing pressure, and intensifying anti CD20 competition could erode market share and strain earnings power.
What The Results Actually Tested At TG Therapeutics
The key development for TG Therapeutics was BRIUMVI driven revenue of US$240.3 million in Q2 2026, lifting total sales to US$240.3 million from US$141.1 million a year earlier, which clearly leaned toward the optimistic growth story. Profit told a different tale as net income slipped to US$7.8 million and net margin narrowed from 20.0% to 3.2%. The evidence cut both ways.
The useful lesson is simple. When a single product carries the story, treat revenue guidance and segment sales as only half the test and track net margin just as closely in each result.
What TG Therapeutics' Price Already Assumes After A 98% Run
TG Therapeutics now trades at US$58.08, so this Narrative's Fair Value sitting below the market indicates it views the current run as pricing in a lot of good news already.
The selected Narrative focuses less on sales risk and more on whether BRIUMVI-heavy economics, cost creep and governance questions limit how much profit actually shows up. The key question for anyone paying today is whether BRIUMVI expansion and new programs can cover rising R&D, manufacturing and governance-related drag on earnings.
"The main thing that has to go right is that the company converts the current BRIUMVI patient base, lifecycle programs, and emerging pipeline into durable, high margin recurring earnings while managing rising operating costs and any governance overhang from the ongoing investigation."
One Narrative disagrees with today's price. → See where this Narrative says TG Therapeutics should trade
Find Your Own Contrarian Opportunity
By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.
-
Company 1 - 44% below our estimate - embeds design and engineering earlier in hardware projects through a sketch-to-scale model.
-
Company 2 - 32% below our estimate - scales high capacity AI superclusters that extend a partner's existing cloud infrastructure footprint.
-
Company 3 - 40% below our estimate - expands beyond trackers into storage and inverter add ons tied to a growing installed base.
That is three of the list. See the full list of 30 companies trading below our fair value estimates →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TGTX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
